BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 9118822)

  • 1. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.
    Wilde MI; Markham A
    Drugs; 1996 Nov; 52(5):773-94. PubMed ID: 9118822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders.
    Ye JH; Ponnudurai R; Schaefer R
    CNS Drug Rev; 2001; 7(2):199-213. PubMed ID: 11474424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron.
    Goldsmith B
    Acta Oncol; 2004 Sep; 43 Suppl 15():19-22. PubMed ID: 15370626
    [No Abstract]   [Full Text] [Related]  

  • 5. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serotonin antagonists in the treatment of postoperative nausea and vomiting].
    Schousboe BM; Rovsing ML; Knudsen KE; Borgbjerg FM
    Ugeskr Laeger; 1998 Jun; 160(26):3939-43. PubMed ID: 9656839
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of morphine discontinuation phenomenon in mice by ondansetron, a selective 5-HT3 antagonist.
    Roychoudhury M; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 1996 Dec; 18(10):677-83. PubMed ID: 9121224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology].
    Csáki C; Ferencz T; Koós R; Schuler D; Borsi J
    Orv Hetil; 1993 Jun; 134(25):1363-7. PubMed ID: 8332356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?
    Maxton DG; Morris J; Whorwell PJ
    Aliment Pharmacol Ther; 1996 Aug; 10(4):595-9. PubMed ID: 8853764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting.
    Burnette PK; Perkins J
    Pharmacotherapy; 1992; 12(2):120-31. PubMed ID: 1533280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectrum of use and tolerability of 5-HT3 receptor antagonists.
    Haus U; Späth M; Färber L
    Scand J Rheumatol Suppl; 2004; 119():12-8. PubMed ID: 15515406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs.
    Kiesewetter B; Duan H; Lamm W; Haug A; Riss P; Selberherr A; Scheuba C; Raderer M
    Oncologist; 2019 Feb; 24(2):255-258. PubMed ID: 30171068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ondansetron. Therapeutic use as an antiemetic.
    Milne RJ; Heel RC
    Drugs; 1991 Apr; 41(4):574-95. PubMed ID: 1711961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nurses' perceptions of antiemetic effectiveness.
    Rhodes VA; McDaniel RW; Simms SG; Johnson M
    Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
    Kaushal J; Gupta MC; Kaushal V; Bhutani G; Dhankar R; Atri R; Verma S
    Singapore Med J; 2010 Nov; 51(11):871-5. PubMed ID: 21140114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
    Egan AP; Taggart JR; Bender CM
    Oncol Nurs Forum; 1992 Jun; 19(5):791-5. PubMed ID: 1535124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
    ; Wong RK; Paul N; Ding K; Whitehead M; Brundage M; Fyles A; Wilke D; Nabid A; Fortin A; Wilson D; McKenzie M; Ackerman I; Souhami L; Chabot P; Pater J
    J Clin Oncol; 2006 Jul; 24(21):3458-64. PubMed ID: 16849762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of paroxetine on intestinal motility in the presence of ondansetron.
    Afzal A; Khan A; Khan A; Farooqi R; Khan BT; Ara I
    Pak J Pharm Sci; 2020 May; 33(3):1169-1172. PubMed ID: 33191244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ondansetron: a new entity in emesis control.
    Graves T
    DICP; 1990 Nov; 24(11 Suppl):S51-4. PubMed ID: 2148659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.